Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871194 | 0.91 | EDNRA (0.42) | KDM4EATML3MBTL1EDNRBEDNRA | |
| SCHEMBL18563232 | 0.89 | L3MBTL1 (0.42) | KDM4EATML3MBTL1EDNRBEDNRA | |
| SCHEMBL17722183 | 0.86 | L3MBTL1 (0.50) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL713969 | 0.86 | L3MBTL1 (0.50) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL18563262 | 0.85 | KDM4E (0.44) | KDM4EATML3MBTL1EDNRBEDNRA | |
| SCHEMBL24948444 | 0.85 | L3MBTL1 (0.49) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL24948441 | 0.85 | L3MBTL1 (0.49) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL24947984 | 0.85 | L3MBTL1 (0.49) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL24973597 | 0.85 | L3MBTL1 (0.49) | KDM4EATML3MBTL1TSPOHDAC4 | |
| SCHEMBL20812971 | 0.85 | L3MBTL1 (0.49) | KDM4EATML3MBTL1TSPOHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012606-B2 | Heterocyclic compound and organic electroluminescent device using the same | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012606-B2 | Heterocyclic compound and organic electroluminescent device using the same | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090153031-A1 | Heterocyclic compound and organic electroluminescent device using the same | NIPPON STEEL CHEMICAL CO., LTD (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090153031-A1 | Heterocyclic compound and organic electroluminescent device using the same | NIPPON STEEL CHEMICAL CO., LTD (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090153031-A1 | Heterocyclic compound and organic electroluminescent device using the same | ORC3, NAP1L4, NR4A2 | KDM4E 1619/4885ATM 3596/4885L3MBTL1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.